Related references
Note: Only part of the references are listed.CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
Bob Olsson et al.
LANCET NEUROLOGY (2016)
The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
Kaj Blennow et al.
Frontiers in Neuroscience (2015)
STANNIOCALCIN 1 IS IMPORTANT FOR POSTSTROKE FUNCTIONALITY, BUT DISPENSABLE FOR ISCHEMIC TOLERANCE
A. Durukan Tolvanen et al.
NEUROSCIENCE (2013)
Evolution and roles of stanniocalcin
B. H. Y. Yeung et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
Association of Higher Levels of High-Density Lipoprotein Cholesterol in Elderly Individuals and Lower Risk of Late-Onset Alzheimer Disease
Christiane Reitz et al.
ARCHIVES OF NEUROLOGY (2010)
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Kaj Blennow et al.
NATURE REVIEWS NEUROLOGY (2010)
CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies
Fredrik Bostrom et al.
NEUROBIOLOGY OF AGING (2009)
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease
Katharina Buerger et al.
BRAIN (2006)
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
O Hansson et al.
LANCET NEUROLOGY (2006)
Global prevalence of dementia: a Delphi consensus study
CP Ferri et al.
LANCET (2005)
Stanniocalcin 1 as a pleiotropic factor in mammals
Y Yoshiko et al.
PEPTIDES (2004)
Stanniocalcin in terminally differentiated mammalian cells
M Serlachius et al.
PEPTIDES (2004)
The future of stroke treatment
PJ Lindsberg et al.
NEUROLOGIC CLINICS (2000)
Share Paper
